Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

Heartburn News

News
Vonoprazan vs Esomeprazole for Treating Symptomatic Gastroesophageal Reflux Disease
11/14/2022
Maria Asimopoulos
Investigators compared the efficacy and safety of vonoprazan and esomeprazole in patients with gastroesophageal reflux disease who responded only partially to proton pump inhibitors.
Investigators compared the efficacy and safety of vonoprazan and esomeprazole in patients with gastroesophageal reflux disease who responded only partially to proton pump inhibitors.
Investigators compared the...
11/14/2022
Pharmacy Learning Network
News
Adding Dopamine Antagonist to PPI Therapy for GERD
10/18/2022
Jolynn Tumolo
“Although PPIs are first-line medications for GERD, up to one-third of patients do not experience symptom relief after an 8-week course of PPI therapy," researchers said.
“Although PPIs are first-line medications for GERD, up to one-third of patients do not experience symptom relief after an 8-week course of PPI therapy," researchers said.
“Although PPIs are first-line...
10/18/2022
Pharmacy Learning Network
News
Vonoprazan vs PPIs for Treating Heartburn in Patients With Erosive Esophagitis
09/13/2022
Maria Asimopoulos
In a systematic review and meta-analysis, researchers compared the efficacy of vonoprazan and proton pump inhibitors for resolving heartburn in patients with erosive esophagitis.
In a systematic review and meta-analysis, researchers compared the efficacy of vonoprazan and proton pump inhibitors for resolving heartburn in patients with erosive esophagitis.
In a systematic review and...
09/13/2022
Pharmacy Learning Network

Advertisement

News
Heartburn Center Successfully Centralizes Care in a Community Setting
12/22/2021
Jolynn Tumolo
Integrating a comprehensive heartburn center in a community setting was commercially viable and boosted patient satisfaction, according to recent findings.
Integrating a comprehensive heartburn center in a community setting was commercially viable and boosted patient satisfaction, according to recent findings.
Integrating a comprehensive...
12/22/2021
Pharmacy Learning Network
News
Proton Pump Inhibitors May Reduce Severity of Gum Disease
11/08/2021
Jolynn Tumolo
“Proton pump inhibitors (PPIs) are commonly prescribed for the management of acid-related gastrointestinal disorders,” researchers explained. “PPIs could potentially be used in combination with other periodontal treatments."
“Proton pump inhibitors (PPIs) are commonly prescribed for the management of acid-related gastrointestinal disorders,” researchers explained. “PPIs could potentially be used in combination with other periodontal treatments."
“Proton pump inhibitors (PPIs)...
11/08/2021
Pharmacy Learning Network
News
Research Identifies OTC Meds Commonly Involved in Drug-Drug Interactions
10/08/2021
Jolynn Tumolo
“The most significant finding,” Dr Oliver wrote, “was the lack of high-quality evidence for commonly acknowledged interactions. High-quality interaction studies involving different phenotypes in drug metabolism (cytochrome P450) and...
“The most significant finding,” Dr Oliver wrote, “was the lack of high-quality evidence for commonly acknowledged interactions. High-quality interaction studies involving different phenotypes in drug metabolism (cytochrome P450) and...
“The most significant finding,”...
10/08/2021
Pharmacy Learning Network

Advertisement

News
Pharmacist Intervention Improved PPI Use Among Patients With Heartburn, Other Acid-related Disorders
09/23/2021
Jolynn Tumolo
“In a busy inpatient setting, we developed a feasible way to assess PPI therapy, deimplement nonguideline-concordant PPI use, and provide follow-up to assess any unintended consequences,” explained researchers.
“In a busy inpatient setting, we developed a feasible way to assess PPI therapy, deimplement nonguideline-concordant PPI use, and provide follow-up to assess any unintended consequences,” explained researchers.
“In a busy inpatient setting, we...
09/23/2021
Pharmacy Learning Network
News
Prescription-Strength Heartburn Drug Recalled
11/13/2020
A Class II recall is active for a prescription proton-pump inhibitor that treats stomach ulcers, gastroesophageal reflux disease, and high levels of stomach acid.
A Class II recall is active for a prescription proton-pump inhibitor that treats stomach ulcers, gastroesophageal reflux disease, and high levels of stomach acid.
A Class II recall is active for...
11/13/2020
Pharmacy Learning Network
News
OTC Heartburn Medication Recalled
12/13/2019
Sanofi-Aventis US issued a precautionary, voluntarily recall of all over-the-counter Zantac (ranitidine) products because of possible contamination with NDMA.
Sanofi-Aventis US issued a precautionary, voluntarily recall of all over-the-counter Zantac (ranitidine) products because of possible contamination with NDMA.
Sanofi-Aventis US issued a...
12/13/2019
Pharmacy Learning Network

Advertisement

News
Heartburn Drug Recalled
11/08/2019
The FDA is recalling nearly 70,000 bottles of an antacid and antihistamine used to treat heartburn, stomach ulcers, and gastroesophageal reflux disease.
The FDA is recalling nearly 70,000 bottles of an antacid and antihistamine used to treat heartburn, stomach ulcers, and gastroesophageal reflux disease.
The FDA is recalling nearly...
11/08/2019
Pharmacy Learning Network

Advertisement

Advertisement

Stay Informed & Sign Up Today

Pharmacy Learning Network Newsletter

Advertisement

Advertisement

Video Insights

Videos
David Rubin, MD, on JAK Inhibitors: Small But Mighty
11/22/2023

Featuring David Rubin, MD

Featuring David Rubin, MD
Dr Rubin reviews his presentation from the Advances in Inflammatory Bowel Disease regional meeting on the latest information on the safety and efficacy of Janus kinase inhibitors for the treatment of inflammatory bowel disease.
Dr Rubin reviews his presentation from the Advances in Inflammatory Bowel Disease regional meeting on the latest information on the safety and efficacy of Janus kinase inhibitors for the treatment of inflammatory bowel disease.
Dr Rubin reviews his...
11/22/2023
Pharmacy Learning Network
Videos
Advantages and Drawbacks of Lecanemab in Alzheimer Disease Treatment
11/10/2023

Featuring Paul Schulz, MD 

Featuring Paul Schulz, MD 
Dr Shulz discusses the FDA-approved lecanemab for the treatment of AD.
Dr Shulz discusses the FDA-approved lecanemab for the treatment of AD.
Dr Shulz discusses the...
11/10/2023
Pharmacy Learning Network
Videos
Immunosuppressants or Immunomodulators? Biologic Agents for Psoriasis
10/27/2023

Featuring Ronald Vender, MD, FRCPC

Featuring Ronald Vender, MD, FRCPC ...
In this exclusive interview, Dr Ronald Vender goes over the highly effective targeted biologic therapies used to treat psoriasis.
In this exclusive interview, Dr Ronald Vender goes over the highly effective targeted biologic therapies used to treat psoriasis.
In this exclusive interview, Dr...
10/27/2023
Pharmacy Learning Network
Videos
Application of Dupilumab to Pediatric Patients With Atopic Dermatitis
10/27/2023

Featuring Abigail Cline, MD, PhD, FAAD

Featuring Abigail Cline, MD, PhD, FAA...
In this feature video, Dr Abigail Cline discusses current literature to assess reported efficacies, side effects, and risks of using dupilumab to treat atopic dermatitis in pediatric patients.
In this feature video, Dr Abigail Cline discusses current literature to assess reported efficacies, side effects, and risks of using dupilumab to treat atopic dermatitis in pediatric patients.
In this feature video, Dr...
10/27/2023
Pharmacy Learning Network
Videos
Patient Considerations When Prescribing Lecanemab for Alzheimer Disease
10/06/2023

Featuring Paul Schulz, MD

Featuring Paul Schulz, MD
Dr Paul Schulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Schulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Schulz discusses the...
10/06/2023
Pharmacy Learning Network
Headshots of Chris Fausel, PharmD, MHA, BCOP; Erin Hamai Tom, PharmD, APh, MBA, BCACP; and Ryan Nix, PharmD, MMHC
Videos
Specialty Pharmacy Next: Focus on Distribution Processes, Data Utilization, New Drugs, and More
07/18/2023

Featuring Chris Fausel, PharmD, MHA, BCOP; Erin Hamai Tom, PharmD, APh, MBA, BCACP; and Ryan Nix, PharmD, MMHC

Featuring Chris Fausel, PharmD, MHA, ...
In this roundtable, cochairs of Specialty Pharmacy Next gather to discuss pertinent topics on the agenda such as white and brown bagging practices and data usage for program growth, as well as who may benefit most from attending the meeting.
In this roundtable, cochairs of Specialty Pharmacy Next gather to discuss pertinent topics on the agenda such as white and brown bagging practices and data usage for program growth, as well as who may benefit most from attending the meeting.
In this roundtable, cochairs of...
07/18/2023
Pharmacy Learning Network
Videos
Leaders in Pharmacy Come Together to Discuss and Debate Oncology-Related Developments
06/28/2021
Julie Gould
Chris Fausel, PharmD, Val Adams, PharmD, Kirollos Hanna, PharmD, and Lisa Holle, PharmD, cochairs of Great Debates and Updates Oncology Pharmacy, come together to discuss this new CPE event aimed at educating pharmacists interested in...
Chris Fausel, PharmD, Val Adams, PharmD, Kirollos Hanna, PharmD, and Lisa Holle, PharmD, cochairs of Great Debates and Updates Oncology Pharmacy, come together to discuss this new CPE event aimed at educating pharmacists interested in...
Chris Fausel, PharmD, Val Adams,...
06/28/2021
Pharmacy Learning Network
Expanded FDA Approval Improves Care Access, Rates of Flu Cases
Videos
Expanded FDA Approval Improves Care Access, Rates of Flu Cases
04/19/2021
Gregg Sylvester, MD, MPH, chief medical officer, and David Ross, vice president, commercial operations for North America, both at Seqirus, discuss the recent FDA approval for Flucelvax Quadrivalent, explain what the expanded indication means...
Gregg Sylvester, MD, MPH, chief medical officer, and David Ross, vice president, commercial operations for North America, both at Seqirus, discuss the recent FDA approval for Flucelvax Quadrivalent, explain what the expanded indication means...
Gregg Sylvester, MD, MPH, chief...
04/19/2021
Pharmacy Learning Network
Identifying Drug Diversion Differences in Retail Pharmacies Compared With Health Systems
Videos
Identifying Drug Diversion Differences in Retail Pharmacies Compared With Health Systems
12/28/2020
Tom Knight, founder and CEO, Invistics, identifies drug diversion differences in a hospital or health system versus a retail pharmacy, and explains what retail pharmacies can do to better detect and address drug diversion.
Tom Knight, founder and CEO, Invistics, identifies drug diversion differences in a hospital or health system versus a retail pharmacy, and explains what retail pharmacies can do to better detect and address drug diversion.
Tom Knight, founder and CEO,...
12/28/2020
Pharmacy Learning Network
Identifying Risks of Human Error, Workarounds in Pharmacy
Videos
Identifying Risks of Human Error, Workarounds in Pharmacy
12/22/2020
Matthew Grissinger, RPh, FISMP, FASCP, director of Error Reporting Programs, Institute for Safe Medication Practices, discusses how human error, various at-risk behaviors, as well as workarounds taken by staff members all impact outcomes and...
Matthew Grissinger, RPh, FISMP, FASCP, director of Error Reporting Programs, Institute for Safe Medication Practices, discusses how human error, various at-risk behaviors, as well as workarounds taken by staff members all impact outcomes and...
Matthew Grissinger, RPh, FISMP,...
12/22/2020
Pharmacy Learning Network

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use